Does the media prefer ALNY or ABVX?

In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 18 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.09 beat Abivax's score of -0.17 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Abivax 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ABVX or BIIB?

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Biogen $9.89B 3.40 $1.29B $5.65 40.27

Is ABVX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Biogen 8.32% 11.18% 6.88%

Does the media favor ABVX or BIIB?

In the previous week, Abivax had 3 more articles in the media than Biogen. MarketBeat recorded 18 mentions for Abivax and 15 mentions for Biogen. Biogen's average media sentiment score of 0.76 beat Abivax's score of -0.17 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ABVX or ROIV?

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Roivant Sciences $8.26M 3,219.83 -$299.77M -$0.53 N/A

Is ABVX or ROIV more profitable?

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media favor ABVX or ROIV?

In the previous week, Abivax had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Abivax and 13 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.37 beat Abivax's score of -0.17 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, INSM or ABVX?

Abivax has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 42.62 -$1.28B -$4.11 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is INSM or ABVX more profitable?

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -91.69% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Abivax N/A -91.69% -71.96%

Does the media refer more to INSM or ABVX?

In the previous week, Abivax had 8 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Abivax and 10 mentions for Insmed. Insmed's average media sentiment score of 0.66 beat Abivax's score of -0.17 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ABVX or INCY?

Incyte has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Incyte $5.14B 4.91 $1.29B $7.85 15.88

Is ABVX or INCY more profitable?

Incyte has a net margin of 27.71% compared to Abivax's net margin of 0.00%. Incyte's return on equity of 29.93% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Incyte 27.71% 29.93% 22.88%

Does the media favor ABVX or INCY?

In the previous week, Incyte had 3 more articles in the media than Abivax. MarketBeat recorded 21 mentions for Incyte and 18 mentions for Abivax. Incyte's average media sentiment score of 0.45 beat Abivax's score of -0.17 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Incyte 5 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Abivax (ABVX) Competitors

$94.13 -4.16 (-4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$95.08 +0.95 (+1.00%)

As of 07:45 PM Eastern

Compare

ABVX vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy Abivax stock or one of its competitors? Abivax's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abivax compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Abivax's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Abivax	N/A	-91.69%	-71.96%

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.88	$313.75M	$5.38	45.82
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 18 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.09 beat Abivax's score of -0.17 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals presently has a consensus target price of $367.20, indicating a potential upside of 48.96%. Abivax has a consensus target price of $156.69, indicating a potential upside of 66.46%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Abivax has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Abivax on 12 of the 15 factors compared between the two stocks.

How does Abivax compare to Biogen?

Abivax (NASDAQ:ABVX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Biogen	$9.89B	3.40	$1.29B	$5.65	40.27

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Biogen	8.32%	11.18%	6.88%

Abivax currently has a consensus target price of $156.69, suggesting a potential upside of 66.46%. Biogen has a consensus target price of $230.14, suggesting a potential upside of 1.15%. Given Abivax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Abivax is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

47.9% of Abivax shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

In the previous week, Abivax had 3 more articles in the media than Biogen. MarketBeat recorded 18 mentions for Abivax and 15 mentions for Biogen. Biogen's average media sentiment score of 0.76 beat Abivax's score of -0.17 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to Roivant Sciences?

Abivax (NASDAQ:ABVX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Abivax had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Abivax and 13 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.37 beat Abivax's score of -0.17 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Roivant Sciences	$8.26M	3,219.83	-$299.77M	-$0.53	N/A

Abivax presently has a consensus price target of $156.69, suggesting a potential upside of 66.46%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 23.94%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Summary

Roivant Sciences beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Abivax compare to Insmed?

Insmed (NASDAQ:INSM) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Abivax has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.62	-$1.28B	-$4.11	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -91.69% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Abivax	N/A	-91.69%	-71.96%

Insmed currently has a consensus target price of $204.91, indicating a potential upside of 73.16%. Abivax has a consensus target price of $156.69, indicating a potential upside of 66.46%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Abivax had 8 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Abivax and 10 mentions for Insmed. Insmed's average media sentiment score of 0.66 beat Abivax's score of -0.17 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.9% of Abivax shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Insmed beats Abivax on 9 of the 16 factors compared between the two stocks.

How does Abivax compare to Incyte?

Abivax (NASDAQ:ABVX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Abivax's net margin of 0.00%. Incyte's return on equity of 29.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Incyte	$5.14B	4.91	$1.29B	$7.85	15.88

In the previous week, Incyte had 3 more articles in the media than Abivax. MarketBeat recorded 21 mentions for Incyte and 18 mentions for Abivax. Incyte's average media sentiment score of 0.45 beat Abivax's score of -0.17 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	5 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

47.9% of Abivax shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abivax currently has a consensus target price of $156.69, indicating a potential upside of 66.46%. Incyte has a consensus target price of $124.05, indicating a potential downside of 0.47%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts plainly believe Abivax is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Incyte beats Abivax on 11 of the 15 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.59B	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-15.53	7.95	209.51	20.92
Price / Sales	N/A	1,367.44	649.76	88.01
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	14.33	15.30	10.44	6.32
Net Income	-$380.27M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.92%	-0.22%	0.51%	1.35%
1 Month Performance	-18.11%	-6.06%	-3.38%	-3.68%
1 Year Performance	14.76%	34.37%	16.04%	5.56%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	2.3746 of 5 stars	$94.13 -4.2%	$156.69 +66.5%	+19.6%	$8.59B	N/A	N/A	69	Trending News Earnings Report Analyst Forecast High Trading Volume
ALNY Alnylam Pharmaceuticals	4.1993 of 5 stars	$241.77 -1.5%	$367.20 +51.9%	-45.2%	$32.34B	$3.71B	44.92	2,770	Analyst Forecast
BIIB Biogen	2.7284 of 5 stars	$216.95 -1.0%	$230.14 +6.1%	+60.2%	$32.06B	$9.89B	38.40	7,500
ROIV Roivant Sciences	3.2112 of 5 stars	$40.05 +0.2%	$41.42 +3.4%	+155.8%	$28.90B	$7.53M	N/A	721
INSM Insmed	3.1973 of 5 stars	$120.44 -2.9%	$204.91 +70.1%	-16.7%	$26.30B	$1.14B	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors

ABVX vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Abivax compare to Alnylam Pharmaceuticals?

Summary

How does Abivax compare to Biogen?

Summary

How does Abivax compare to Roivant Sciences?

Summary

How does Abivax compare to Insmed?

Summary

How does Abivax compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abivax (ABVX) Competitors

ABVX vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Abivax compare to Alnylam Pharmaceuticals?

Is ALNY or ABVX more profitable?

Do institutionals and insiders believe in ALNY or ABVX?

Which has better valuation and earnings, ALNY or ABVX?

Does the media prefer ALNY or ABVX?

Do analysts recommend ALNY or ABVX?

Which has more volatility & risk, ALNY or ABVX?

Summary

How does Abivax compare to Biogen?

Which has preferable valuation & earnings, ABVX or BIIB?

Is ABVX or BIIB more profitable?

Do analysts rate ABVX or BIIB?

Do institutionals & insiders hold more shares of ABVX or BIIB?

Which has more volatility & risk, ABVX or BIIB?

Does the media favor ABVX or BIIB?

Summary

How does Abivax compare to Roivant Sciences?

Do institutionals and insiders have more ownership in ABVX or ROIV?

Does the media favor ABVX or ROIV?

Which has stronger earnings & valuation, ABVX or ROIV?

Do analysts prefer ABVX or ROIV?

Which has more risk & volatility, ABVX or ROIV?

Is ABVX or ROIV more profitable?

Summary

How does Abivax compare to Insmed?

Which has stronger earnings & valuation, INSM or ABVX?

Which has more volatility and risk, INSM or ABVX?

Is INSM or ABVX more profitable?

Do analysts recommend INSM or ABVX?

Does the media refer more to INSM or ABVX?

Do insiders and institutionals believe in INSM or ABVX?

Summary

How does Abivax compare to Incyte?

Which has more risk and volatility, ABVX or INCY?

Is ABVX or INCY more profitable?

Which has better valuation & earnings, ABVX or INCY?

Does the media favor ABVX or INCY?

Do institutionals & insiders hold more shares of ABVX or INCY?

Do analysts rate ABVX or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools